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Magdalena Blaszczyk-Thurin, Ph.D. The tumor cell-endothelial-cell (EC) interaction, specifically that between E-selectin on EC and carbohydrate ligands on leukocytes and tumor cells, has recently emerged as a promising target for cancer therapy. The carbohydrate structures sialyl-Lewis X (SA-LeX), sialyl-Lewis a (SA-Lea) and Lewis Y (LeY) are the key factor underlying the metastatic potential of carcinoma cells. The proposed studies explored the possibility of generating peptide mimetics to interrupt adhesion of tumor cells to vascular endothelium and thereby significantly reduce metastatic spread in analogy with reduction of neutrophil recruitment in chronic inflammation. We have identified a panel of 12-mer peptides from a random peptide library using monoclonal antibodies (MAbs) specific for human tumor-associated carbohydrate antigens, i.e., SA-Lea, SA-LeX and LeY, and the peptides were proven to retain a carbohydrate-like conformation. Most importantly they can block selectin function in vivo. In addition to the originally proposed studies, we have identified a panel of peptides mimicking E-selectin ligand(s) using E-selectin-IgG immunoglobulin fusion protein and applied peptide array based on the selected peptides to characterize amino acids important for MAb/E-selectin interaction as well as tc identify peptides with increased binding ability. We established syngeneic murine models and are in a process of applying the identified peptides as anti-adhesion therapy against development of metastasis. These studies provide significant information pertinent to new strategies for therapeutic intervention for human cancer and insight into the role of adhesion and carbohydrate determinants in the metastatic process.
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XrIn conducting research using animals, the investigator(s) adhered to the "Guide for the Care ..................................................................................................................................... Carbohydrate ligands such as SA-LeX and SA-Le' are found on the surface of leukocytes and tumor cells, and their receptor, E-selectin, is expressed on activated endothelial cells. An objective of the proposed studies was to explore the possibility that interruption of protein-carbohydrate based adhesion of tumor cells to vascular endothelium reduces significantly metastatic spread in analogy with reduction of neutrophil recruitment in inflammatory conditions.
Specifically we proposed to use combinatorial libraries to identify structural equivalents or peptide mimotopes of carbohydrate ligands for E-selectin such as SA-Lea and SA-LeX and E-selectin independent adhesion ligand LeY using specific MAbs and to investigate the effect of the identified peptides for their ability to interfere with tumor cell attachment in vitro using various adhesion assays and metastatic processes in vivo.
Aberrant glycosylation in tumors. Aberrant glycosylation in tumors relative to their normal counterparts represents a phenotypic feature associated with different human malignancies (1) . This phenomenon has been demonstrated repeatedly at frequencies higher than those of oncogenes and suppressor genes in various tumors. Aberrant glycosylation is crucial in tumor progression, since cells acquire competence for metastasis and faster clonal growth via newly synthesized carbohydrate structures. Several types of altered glycosylation have been described in human carcinomas and among others enhanced expression of Lewis antigens such as sialyl-Lea (SA-Lea) [NeuAcC(2,3Gal3l,3(FuccXl,4) GlcNAcI31,3Gal 31,4Glc3 l-R] and sialyl-LeX (SA-LeX) [NeuAca2,3GalI31,4(Fuca 1,3) GlcNAc P31,3 Gall31,4Glc3 1 -R] is observed more frequently than their respective nonsialylated forms (2-4). These structures were previously determined by us and others as being highly tumor-associated antigens in human adenocarcinomas. SA-LeX and SA-Lea are recognized by members of the selectin endothelial adhesion molecules family and are postulated to be involved in metastatic spread.
Selectin-mediated adhesion of tumor cells. Selectins as a family of adhesion molecules are known to mediate critical cell-cell interactions in processes such as leukocyte trafficking, thrombosis, acute and chronic inflammation and ischemia reperfusion injury (5-7). Selectins support the adhesion of leukocytes to the vessel wall through the recognition of specific carbohydrate structures such as SA-LeX.
SA-LeX and its isomer SA-Lea are tumor-specific oligosaccharides recognized by selectins and the metastatic potential of a variety of malignant cells is related to the functional expression of these ligands. Previous studies demonstrated that carcinoma cells bind to activated EC by E-selectin-dependent mechanism (8) (9) (10) (11) . Once tumor cells adhere to EC, they penetrate through the EC layer, moving into subendothelial tissues where metastasis is established. The expression of ligands for E-selectin by both neutrophils and carcinoma cells, raises the possibility that metastases are equivalent to the inflammatory process in which tumor cells, particularly carcinoma cells, use the same molecular mechanism(s) for cancer cell-EC interaction as lymphocytes, through the action of the endothelial selectins with the tumor-associated carbohydrate ligands, e.g. SA-LeX and SA-Lea. Although adhesion pathways utilized by different tumors show considerable diversity, recent reports clearly suggest that at least one member of the selectin family of molecules and SA-Lea and/or SA-LeX carbohydrate ligands, both highly expressed on the tumor cell surface, might be involved in tumor metastasis by mediating binding of blood-borne tumor cells via Eand/or P-selectin to vascular endothelium (8) (9) (10) (11) . In particular, E-selectin is postulated to be the most efficient selectin, mediating rolling of cancer cells to EC and SA-Lea plays a major role as a ligand in the Eselectin dependent adhesion to EC. Cancer cells that express both SA-Lea and SA-LeX undergo SA-Lea mediated adhesion almost exclusively, possibly due to a higher affinity for the SA-Lea structure or differential presentation of the oligosaccharide determinant. SA-Lea specific MAbs including NS 19-9, which we propose to use to identify SA-Lea mimicking peptides, were inhibitory for adhesion of colon carcinoma cells to human umbilical cord vein endothelial cells. In addition, to interrupt the metastatic process at the level of cellular adhesion, these compounds should interfere with blood vessel formation since E-selectin and SA-LeX are expressed on actively growing blood vessels.
E-selectin independent adhesion of tumor cells. Antibodies BR55-2 and BR15-6A directed to LeY significantly decreased the adhesion in a dose-dependent fashion, implicating the involvement of LeY in adhesion of these breast carcinoma cells. These data indicate that different human adenocarcinoma cells interact with EC via E-selectin-mediated and E-selectin-independent pathways in agreement with previously published reports that some invasive breast carcinoma cells do not interact with TNF-c(x-stimulated EC under dynamic conditions, but adhere to resting and stimulated EC via an E-selectin independent mode following static incubation (12, 13) .
Therapeutic inhibition of carbohydrate-protein interaction.
Although all selectins share specificity for SA-LeX, the requirements for binding to E-selectin are distinct from those of P-selectin, because, for example PGSL-1 does not require tyrosine sulfation for binding to E-selectin (14) . Unlike the case for P-and L-selectin, the presentation of SA-LeX and SA-Lea ligands for E-selectin is not limited to mucin type glycoproteins since they are present on 0-linked and N-linked oligosaccharides, as well as glycosphingolipids, suggesting mainly unmodified oligosaccharide recognition of E-selectin. Furthermore, SA-LeX was demonstrated to be able to sustain rolling of SA-Lea-containing microspheres on E-selectin in a flow adhesion system (15) . These observations support the key role of SA-LeX/SA-Lea oligosaccharides as adhesion ligands for E-selectin. Thus, it is possible that in vivo blocking of selectin-dependent adhesion may even be more effective with ligand antagonists than with the native ligands and/or antagonists based on the protein of individual selectins, since it will affect binding of all selectin family members. Thus, instead of using receptors for screening of combinatorial libraries, we proposed to use MAbs that specifically recognize ligands for endothelial adhesion molecules. The advantage of peptide library screening with the MAb is that the peptides mimic respective carbohydrate that can display binding cross-reactivity for all selectins since all selectins display specificity for the same ligand. The crucial role of selectin-dependent neutrophil adhesion and carcinoma cell-adhesion in their recruitment process implies that in vivo blockage of selectin-dependent interaction can decrease leukocyte mobilization and the severity of the metastatic process, respectively. Fifty to 70% inhibition of neutrophil recruitment with monoclonal antibodies and selectin-Ig chimeras was demonstrated (16) comparable to L-selectin-deficient mice (17) in studies of a mouse model of peritonitis. Identification of the structure of selectin ligands has provided the opportunity to test oligosaccharide ligands and their derivatives for anti-inflammatory effect in vivo despite their rather low binding affinity to the receptor. Derivatives of SA-LeX oligosaccharide prevented P-and E-selectindependent inflammation in rodent models (24, 25) and in a cat model of myocardial perfusion injury (18) . High-affinity ligands described to date for selectins are acidic polysaccharides such as single-stranded oligonucleotides (19) , heparin (20) , inositol polyanions (21), fucoidan (22) glycyrrhizin, a triterpene glycoside identified using a search of a three-dimensional database (23) as well as a peptide mimetic identified in random peptide library (24) . However, this high-affinity peptide contains an identical sequence (QLWD) to the first four amino acids residues of PSGL-1, which binds to both P-and E-selectin, suggesting protein and not carbohydrate binding. Consequently, this peptide does not define a carbohydrate mimotope as described in this application.
Although these approaches have not been studied in tumor models in vivo as extensively as antiinflammatories, administration of E-selectin-specific antibody and soluble E-selectin abrogated the formation of hepatic metastasis and lung colony formation in vivo (25) (26) (27) . Further, E-selectin transgenic mice, in which E-selectin is expressed in all organs at high levels under the p-actin promoter developed metastasis in lung, liver and mesenteric lymph nodes, and died much faster than wild-type animals (28) . These data imply that similar molecular mechanisms do indeed underlie inflammation and metastasis and that similar therapeutic approaches can be used to intervene with these processes.
METHODS AND PROCEDURES
As part of our effort to develop high-affinity novel molecules to inhibit the adhesion of adenocarcinoma cells to EC, we screened a 12-mer random peptide library for binding to MAbs specific for tumor-associated oligosaccharides SA-Le a (NS 19-9) (Wistar Institute), SA-LeX (FH6) (ATCC) and LeY (BR 15-6A) (Wistar Institute). E-selectin-Ig chimeric protein was obtained from Dr. George Haevner DAMD 17-96-1-6232 (Centocor Inc., Malvern, PA) was also used to identify peptide equivalents of cognate ligands that may involve other structural elements in addition to SA-LeX/SA-Lea carbohydrates.
Random peptide library. In the library we have chosen, random peptides are displayed on the surface of bacteria within the structural context of the thioredoxin which is inserted into flagellin gene and the resulting fusion protein FLITR is expressed on the bacterial cell surface. This enables efficient isolation of these bacteria displaying peptides with affinity to immobilized antibodies or other binding proteins. An aliquot of FLITRX library containing at least 2 x 1010 cells to ensure full representation of peptides, was grown to saturation for 15 hr in IMC/amp 100 medium (M9 medium with 1 mM MgCI 2 , 0.5% glucose, 0.2% casamino acids and 100 gg/mIl ampicilin). The culture of 1010 cells was diluted with fresh IMC/amp 100 medium containing 100 jig/ml tryptophan and incubated for an additional 6 hr. The induced bacteria were panned on an MAb-coated (20 gg/ml) plate followed by blocking with 1% nonfat milk containing 150 mM NaC1 and 1% a-methyl mannoside. After washing, cells were eluted and collected in 10 ml of fresh IMC/amp 100 medium and are incubated at 25°C until saturation. The entire selection process was repeated four more times. Individual colonies were isolated on ampicilin-containing plates and grown in 2 ml rich media. Forty Jtl of culture was induced for protein expression in a 2 ml IMC/amp 100 medium with tryptophan for 6 hr. The clones isolated with carbohydrate-specific MAb in the final selection cycle were tested for protein expression using SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and identified after probing by Western blot with the respective MAb and with E-selectin-IgG (29) . In addition, nitrocellulose filters after protein transfer were probed with MAb specific for thioredoxin to confirm the identity of bands detected with specific MAbs or E-selectin-Ig. Only clones which display strong signal identified on the Western blot with the respective MAb were selected for sequence identification. Expression of the FLITRX fusion protein containing peptide sequences mimicking carbohydrate structures by the bacterial clones was detected with the specific MAb or E-selectin-IgG fusion protein (10 gg/ml). The expression and the location of thioredoxin on the nitrocellulose filter is confirmed after incubation of parallel filters with trxA-specific MAb (anti-ThioTM) (Invitrogen, Carlsbad, CA). Following antibody binding, the filters were washed, incubated with HRP-conjugated goat anti-mouse antibody and treated to a freshly mixed luminol and oxidizing solution for 1 min, air-dried and exposed on a ReflectionTM film (NENTM, Life Sciences Products, Boston, MA).
DNA sequencing. DNA was isolated from the selected bacteria using standard isopropanol precipitation in the presence of potassium acetate using a mini-column DNA purification column (Qiagen, Chatsworth, CA). The phages selected from the third round of biopanning were precipitated with polyethylene glycol after amplification, and single-stranded DNA is prepared by phenol extraction. The nucleotide sequences of the DNA from the selected bacteria or phages were determined by the dideoxynucleotide chain termination method using specific primers at The DNA Facility at The Wistar Institute.
Titration of peptides with MAbs.
The following experiments determined whether the isolated peptides retain conformational properties of carbohydrates in a series of in vitro assays: a) direct binding to respective MAbs and E-selectin-IgG in solid phase and inhibition of MAbs and E-selectin-IgG binding to the cognate carbohydrate ligands in solid phase.
Selected peptides were synthesized by standard solid-phase strategies and HPLC-purified at the Peptide Synthesis Facility of The Wistar Institute. The structures was confirmed by fast-atom bombardment mass spectrometry at The Wistar Institute Protein Sequencing Facility. The binding of MAbs to the immobilized peptide conjugates was measured with ELISA as described (30) . Microtiter plates were coated in coating buffer (15 mM Na 2 CO 3 , 35 mM NaHCO 3 and 3 mM NaN 3 pH 9.6) by air-drying with aliquots of 1 nM to 1 mM peptide and allowed to bind overnight at 37 0 C. Dose-response studies for binding and inhibition of MAb binding to the cognate antigens were run at six concentrations, with sequential dilutions from the initial stock solution giving data points over more than a 5 log concentration range. To avoid non-specific binding, plates were incubated first with 10% y-globulin-free horse serum in PBS for 1 hr. Peptides were then incubated with purified MAb (5 gig/ml in a blocking solution) for 1 hr, washed and incubated for 1 hr with goat anti-mouse Ig conjugated with HRP. The reaction was developed with 3,3'-diaminobenzidine in 50 mM Tris-HCl buffer, pH 7.6 containing 3% H 2 0 2 for 10 min. The color developed was read at 450 nm after stopping the reaction with 1 M phosphoric acid. For peptide competition assays, test peptides at concentrations ranging from 10 nM to 1 mM were preincubated with 100 ll of the respective MAbs (10 jig/ml) at room temperature. After 1 hr incubation, MAb/peptide mixtures were transferred to wells precoated with a constant amount of neoglycoprotein containing coupled multivalent carbohydrate determinants (SA-LeX or SA-Lea PAA) (0.15 jig/well) and allowed to bind for 1 hr. Wells were washed and anti-mouse-HRP antibody and the enzyme substrate are added. IC 50 was calculated by non-linear least-squares regression to a four-parameter logistic equation.
Peptide analogs with enhanced binding. Two approaches were applied to generate structural equivalents of carbohydrate ligands with enhanced affinity: 1) increase of the valency of peptides mimicking carbohydrate structures as discussed below and 2) random mutagenesis using peptide array.
Multivalentpeptides. Multivalency is the critical feature for the interaction of carbohydrates on the cell surface with endolectins such as selectins. SA-LeX/SA-Lea are presented as "oligosaccharide patches" on glycoproteins or on glycosphingolipids clustered on the cell surface, forming polyvalent determinants that enhance the affinity of the selectin-ligand interaction. Thus, particularly important for the development of reagents that will interfere with protein-carbohydrate interactions of EC in vivo is to design molecules with higher binding affinity than the authentic receptor that will be efficient in interrupting this interaction. The presentation of receptor antagonists in multivalent form such as multi-antigen peptide (MAP) should render them considerably more potent as adherence blockers. Multiple antigenic peptides containing eight copies of peptide #4 mimicking SA-Lea on a branched lysine core was acquired commercially (Research Genetics, Huntsville, Inc., AL).
Peptide arrays. Individual substitutions of amino acids in positively identified dodecapeptides were made on a porous membrane (e.g. cellulose paper) by SPOT-Synthesis (31) . This method provides the positionally addressable, parallel chemical synthesis. Briefly, a droplet of liquid applied onto a cellulose membrane is absorbed and spreads as a spot which can form a reactor for chemical conversions. This membrane is stable for 10-20 repeated assays and can be used for Western Blotting. The peptide array are generated in a laboratory of our collaborator in the project, Dr. L. Otvos at the Wistar Institute. We have already obtained a peptide array consisting of 204 dodecamer based on the sequence of peptide #4 mimicking SA-Lea identified by panning with MAb 19-9 which was analyzed by probing membrane with MAbs. The membrane is blocked with 5% milk in PBS-T (pH 6.8) and is allowed to bind the primary antibody in 10 gg/ml for 1 hr. The membrane is washed and treated with HRP-conjugated IgG. Then the binding is detected with the chemiluminescence reagent (NEN) exposure onto a film and the subsequent development. We are currently examining the binding affinity on the peptide array generated from the dodecapeptide selected with E-selectin IgG fusion protein.
Characterization of cell surface expression of SA-LeX, SA-Le' and LeY. To evaluate the ability of the peptides to interfere with the function of endothelial adhesion molecules will be evaluated in syngeneic in vivo model of metastasis. We have characterized the expression of carbohydrate structures in a panel of murine tumor cells.
FACS.
Cells are maintained in DMEM containing 10% FBS and 2 mM glutamine. Expression of carbohydrate antigens was determined with specific MAbs using flow cytometry at The Wistar Institute Flow Cytometry Facility. A single-cell suspension was prepared from adherent cultures by brief trypsinization. Two x 10' cells were stained with a 10 jig/ml solution of MAb in PBS followed by goat anti-mouse fluorescein-conjugated antibody. Incubations with antibodies were for 30 min at room temperature. After the final wash, cells were resuspended in buffer containing 1 jig/ml of propidium iodide to gate out dead cells selectively. Isotype control antibodies were used to determine background staining.
Transfection. Murine tumor cell line expressing SA-Lea determinant was generated by transfection of B 16F10 cells with al,3/4-fucosyltransferase (32). Murine B 16 melanoma cells were transfected with vector containing the hygromycin resistance gene only or with vector itH3M containing cxl,3/4-FTIII. Transfectants were generated by electroporation (Gene Pulser, Bio-Rad Laboratories, Richmond, CA) at 250 V and 960 mF in 4-mm electroporation cuvettes. Clones were selected for hygromycin resistance in 10% FCS/IMDM containing 500 jig/ml hygromycin (Boehringer Mannheim Corp.) and tested for antigen expression by flow cytometry. Using the same transfection procedure MethA cells will be transfected with pCDNA expression vector containing cx1,2-FT cDNA to generate murine cell line expressing LeY.
Experimental inflammatory model. The accumulation of neutrophils is a characteristic feature of acute and chronic inflammatory disease and early steps in the recruitment of these cells to the site of inflammation, depends upon E-selectin-mediated interaction. Thus, inhibition of neutrophil recruitment in vivo is an important test of the ability of potential therapeutic agents to inhibit E-selectin-mediated events. To determine the ability of isolated peptides to inhibit E-selectin function in vivo, the acute inflammatory condition was induced with zymosan injected intraperitoneally (i.p.) into mice followed 3 hr later by an intravenous (i.v.) injection of peptide #4 (1 mg) (33) . Neutrophils were harvested and counted 1 hr later. In control experiments the same dose of Lewis Y mimicking peptide, which does not bind to NS-19-9 MAb was used.
RESULTS
Peptides mimicking carbohydrate structures. Toward the development of novel molecules to inhibit the adhesion of human breast adenocarcinoma cells to EC and ultimately metastasis in vivo, we have characterized peptides derived from a 12-mer random peptide library for binding to antibodies developed in our laboratory, specific to tumor-associated oligosaccharides, LeY (MAb BR15-6A) (34), SA-Lea (MAb NS 19-9) (4) and SA-LeX (MAb FH6) (35) , as well as E-selectin-immunoglobulin chimeric protein (36) .
We have sequenced DNA encoding peptide of several bacterial clones that bind to the SA-Lea structures using MAbs NS 19-9 and E-selectin-IgG and Lewis Y using MAb BR15-6A. The highly conserved core region of each consensus sequence usually is 3 to 5 amino acid long and positional preference of these consensus residues within the dodecapeptide varies. Such positional preference might be a reflection of structural constraints of the inserted peptide imposed by thioredoxin which might limit the position for the antibody binding. Further examination of the sequences reveals that the peptides isolated by BR15-6A and NS 19-9 MAbs and E-selectin-IgG fell into distinct consensus-sequence groups that discriminated between the MAbs and the lectin, and that the native carbohydrate antigens LeY and SA-Lea and the peptides bound only to the MAb or lectin protein used for their isolation.
SA-Lewis a. Two distinct consensus sequences GXWXXVLEG and VVGXP were identified in families of peptides isolated with MAb NS 19-9, which recognizes E-selectin ligand, SA-Lea. The structural relevance of these motifs is unclear. These motifs may indicate the following: i) peptides based on two different motifs isolated with the same MAb can mimic different structural topographies of the cognate SA-Le a carbohydrate; ii) these subset of peptides may very likely represents nonoverlapping surfaces of cognate antigen, and iii) peptide binding to MAb occurs at separate sites. Peptide #4 from NS 19-9 family II mimicking SA-Lea ligand was selected for further studies based on the presence of consensus motif which appeared in multiple bacterial isolates after five rounds of panning (Table 1) . Peptide #4 demonstrated dose-dependent binding with MAb in enzyme-linked immunosorbent assay (ELISA) (data not shown). This peptide was also inhibitory for MAb NS 19-9 binding to the synthetic SA-Le aPAA neoglycoprotein (Glycotech, Inc., Rockville, MD) which contains the cognate oligosaccharide determinant, implying that the sequence DLWDWVVGKPAG represents a solventaccessible epitope. The 50% inhibitory concentration (IC 50 ) value of peptide #4 was calculated at 700 ýtM. Control peptide mimicking Lewis Y carbohydrate structure failed to block antibody binding, indicating that the inhibitory effects of the native sequences are not due to nonspecific effects. Although, the peptide #4 shows relatively low-affinity binding with the antibody, a strong binding signal was observed on the Western blots when the peptide sequence is expressed in the context of thioredoxin. This might be a reflection of structural constraints of the inserted peptide imposed by thioredoxin as compared with the conformation of the peptide in solution or in solid phase.
Acute inflammation model in vivo.
An interaction with SA-Lea, is not relevant for adhesion of neutrophils, since it is not expressed on their surface. In tumor cells, however, E-selectin-mediated interaction with SA-Lea expressed on human cancer cells is preferentially used over SA-LeX to adhere to EC. Nevertheless, because SA-Lea binds to E-selectin, we tested whether administration of a SA-Lea mimicking molecule would diminish the influx of neutrophils into chemically irritated peritoneum in vivo. Peptide treatment significantly (P<0.001) reduced the number of neutrophils in peritoneal lavage fluids (Fig. 1A) . Control experiments using the same dose of Lewis Y mimicking peptide, which does not bind to NS-19-9 MAb, showed no decrease in neutrophil influx relative to PBS-injected mice.
To confirm these results, myeloperoxidase (MPO) activity, which is an enzymatic marker for neutrophils, was measured spectrophotometrically as an absorbance rate in the homogenates of collected cells (33) . Significant reduction of enzymatic activity (P<0.005) was observed in parallel with decreased neutrophil numbers assessed by total neutrophil count (Fig. 1B) . These results strongly suggest that the reduction in enzyme activity is due to reduction in neutrophil recruitment in mice treated with peptide mimicking E-selectin ligand SA-Lea and that this peptide can inhibit E-selectin function in vivo. Characterization of essential amino-acids using peptide array. An array of 204 peptides was prepared based on the amino acid (aa) sequence of peptide #4 isolated from the family 1 with MAb NS 19-9 with all point aa substitutions within the sequence DLWDWVVGKPAG and measured binding of MAb (Fig. 2 ). An analysis of the peptide array suggest that most amino acid (aa) substitutions within C-terminal were tolerated and did not influenced MAb binding, whereas critical residues were clearly identified within the N-terminal. were allowed for MAb binding and no preference for aa was evident from the substituted peptides within the C-terminal. Furthermore, crossreactive peptides, which were formed by multiple aa substitutions were identified. Peptides substituted with F at the 5th position and E at 8th and 9th positions showed significantly stronger signal on the peptide array (Fig. 2) , suggesting that we have identified aa sequences that showed higher binding affinity as compared to the original peptide and that can act as better structural mimics than the peptides identified using combinatorial peptide library. 
E-selectin ligand(s).
To identify peptides mimicking E-selectin ligand, that may involve other than carbohydrate epitopes of the natural ligand, we have initiated screening of the library directly with Eselectin-IgG fusion protein. Among isolated peptides the motif VLSP was found in 7 of 16 clones recovered. In addition, preference for V/G and RR in the sites flanking the 5-amino acid motif were also found. In another group of peptides, a PGR sequence was found in 3 clones. As discussed above, the peptides with different sequence motifs may mimic different topographical surfaces of the cognate carbohydrates or bind to different binding areas of E-selectin combining site.
Lewis Y. Peptide from the family isolated with MAb BR15-6A that inhibits adhesion of human tumor cells to EC in E-selectin independent mode demonstrating sequence motif RPDL, mimicking the LeY carbohydrate was identified using combinatorial library approach. Peptide #7 from the family of LeYmimicking peptides was selected based on a consensus motif which appeared in multiple bacterial isolates after five rounds of panning with the BR15-6A MAb. In vitro studies demonstrated using ELISA that the identified sequence DEVRPDLISTEE represents a putative epitope for the MAb but was not recognized by E-selectin-IgG (data not shown).
In summary, the results suggest that the conformation of the peptides can mimic the topography of the epitopes recognized by MAbs and E-selectin. Data implicate further that the carbohydrate mimotopes are effective in vivo blockade of selectin-dependent interaction, which can diminish leukocyte recruitment in inflammatory process. The data point to the feasibility of using small molecule antagonists isolated from the combinatorial peptide library to block E-selectin function in vivo and will also prove useful to inhibit metastatic process.
In vivo tumor models.
E-selectin-dependent adhesion. An syngeneic model of tumor metastasis was proposed for in vivo studies, in which murine tumor cells derived from the same murine background will be inoculated to form metastasis. We have characterized a panel of human and murine adenocarcinoma cell lines with respect to the expression of the tumor-associated antigens SA-LeX and SA-Lea. MethA fibrosarcoma (kindly provided by Dr. A. DeLeo, University of Pittsburgh), G1261 glioblastoma, CT-26 colon carcinoma, B 16F 1 and B 16F 10 melanoma clones (DCTDC Tumor Repository, NCI, Frederick, MD) and breast adenocarcinoma 66.1, JC, 410.1 cell lines (provided by Dr. A. Fulton, University of Maryland, Baltimore, MD). All cell lines express SA-LeX except B 16F1 and B 16F10 variants, whereas no SA-Lea expression was observed among all cell lines. To extend the syngeneic model to tumors expressing SA-Lea structure, we generated murine tumor cell line stably expressing specific glycosyltransferase, which activity results in synthesis of carbohydrate determinants SA-Lea al ,3/4 fucosyltransferase can mediate synthesis of both ligands, since it is specific for type 1 and 2 lactotetraosyl chain structures, which constitute the core chain of Lewis structures. Thus, the presence of the acceptor for this glycosyltransferase within the cells should guarantee that transfection results in biosynthesis of one or both structures. We have established that B 16F 10 cell line synthesize type 1 lactoseries acceptor structures. The expression vectors containing cDNA of al,3/4 fucosyltransferase (al,3/4FTIII) (provided by Dr. Brian Seed, Massachusetts General Hospital, Boston, MA).
E-selectin-independent adhesion of adenocarcinoma cells.
To generate murine tumor cell line expressing LeY we are currently transfecting MethA and G1261 cell lines with al ,2-fucosyltransferase (al,2FT) available from our previous studies. If LeY expressing murine tumor cells can not be generated, we have characterized a panel of human carcinoma cells expressing LeY, which will be used to establish tumor model in immunodeficient mice. We have demonstrated that human breast adenocarcinoma cell lines, SKBR5 and SKBR3 but not colon adenocarcinoma cells LS 180, SW 1116 and SW948, adhere to TNF-a-stimulated EC and this process is mediated by E-selectin as determined by the inhibitory effect of anti-E-selectin MAb as well as NS 19-9 MAb specific for SA-Le a (not shown).
CONCLUSIONS
SA-LeX and SA-Lea carbohydrate structures are expressed on leukocytes and most human carcinoma cells. Several studies have implicated E-selectin and carbohydrate ligands in leukocytes and carcinoma cell adhesion to the endothelium, an interactions thought to be required for inflammation and tumor extravasation during metastasis. The overall objective of this project was to identify the peptides that mimic oligosaccharide receptors for E-selectin, i.e. SA-LeX and SA-Lea and LeY, which presumably mediated E-selectin independent adhesion of tumor cells to EC and elucidate their effect on tumor cells adhesion to endothelial cells in vitro and abrogate tumor metastasis in vivo.
For the identification of high-affinity inhibitors for E-selectin-mediated tumor cell adhesion we proposed to screen using specific MAbs of recombinant peptide library display technology that has a demonstrated utility in discovering ligands for important therapeutic targets. Highly diverse peptide libraries offer many distinct advantages over difficult chemical or enzymatic synthesis of complex carbohydrates, providing a notably inexpensive and rapid identification and optimization of novel ligands. The binding affinities of the originally identified peptides are KD values at mid-micromolar range, which is comparable with the values obtained for soluble oligosaccharide SA-LeX binding to bivalent E-selectin and with carbohydrate lectin interactions. The IC 50 for SA-LeX binding to E-selectin is 750 nM in competition with bivalent E-selectin-Ig fusion protein binding to immobilized glycoconjugates containing SA-LeX, and a KD of -1.2 mM has been measured by transferred nuclear Overhauser enhancement measurements. Introducing a novel technology such as peptide array into the studies we demonstrated that it provides not only fast method to identify aa residues critical for binding but also to modify the peptides in order to improve their binding ability and efficacy to block protein-ligand interaction. Peptide array was demonstrated to represent powerful method to identify aa substitutions to develop better mimics of DAMD 17-96-1-6232 carbohydrate structures. In addition to the originally proposed in a grant application MAbs we applied for screening of the peptide library E-selectin-IgG chimeric protein to identify mimics of other than SA-Lea and SA-LeX epitopes or ligands. Our results thus far demonstrate that it is possible to isolate carbohydrate mimics that are effective in vivo blockade of selectin-dependent interaction, which can diminish leukocyte recruitment in inflammatory process. The selected peptides mimicking E-selectin ligands are currently tested to confirm their ability to block metastatic process in vivo using murine syngeneic tumors expressing E-selectin ligands that we have established.
In summary, we demonstrated that the use of combinatorial peptide analog technology in combination with synthetic peptide array allow us to identify improved antagonists of E-selectin and other adhesion molecules, which may lead to the further development of agents with greatly enhanced therapeutic potential.
